GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Shiller PE Ratio

Interpace Biosciences (STU:PF42) Shiller PE Ratio : (As of Jun. 07, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Interpace Biosciences Shiller PE Ratio Historical Data

The historical data trend for Interpace Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Shiller PE Ratio Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Interpace Biosciences's Shiller PE Ratio

For the Diagnostics & Research subindustry, Interpace Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Shiller PE Ratio falls into.



Interpace Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Interpace Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Interpace Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.101/131.7762*131.7762
=0.101

Current CPI (Mar. 2024) = 131.7762.

Interpace Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -13.248 100.560 -17.361
201409 -22.504 100.428 -29.529
201412 -40.550 99.070 -53.937
201503 -24.024 99.621 -31.778
201506 -40.986 100.684 -53.643
201509 -27.621 100.392 -36.256
201512 27.173 99.792 35.882
201603 -24.156 100.470 -31.683
201606 -11.481 101.688 -14.878
201609 -36.798 101.861 -47.605
201612 30.715 101.863 39.735
201703 5.142 102.862 6.587
201706 -5.785 103.349 -7.376
201709 -1.259 104.136 -1.593
201712 -1.605 104.011 -2.033
201803 -0.892 105.290 -1.116
201806 -0.599 106.317 -0.742
201809 -0.943 106.507 -1.167
201812 -1.231 105.998 -1.530
201903 -0.832 107.251 -1.022
201906 -1.230 108.070 -1.500
201909 -1.789 108.329 -2.176
201912 -2.601 108.420 -3.161
202003 -2.154 108.902 -2.606
202006 -1.225 108.767 -1.484
202009 -1.307 109.815 -1.568
202012 -1.652 109.897 -1.981
202103 -0.865 111.754 -1.020
202106 -0.697 114.631 -0.801
202109 -0.723 115.734 -0.823
202112 -0.788 117.630 -0.883
202203 -0.481 121.301 -0.523
202206 -0.880 125.017 -0.928
202209 -3.384 125.227 -3.561
202212 -0.349 125.222 -0.367
202303 0.075 127.348 0.078
202306 0.037 128.729 0.038
202309 0.000 129.860 0.000
202312 0.183 129.419 0.186
202403 0.101 131.776 0.101

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Interpace Biosciences  (STU:PF42) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Interpace Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (STU:PF42) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines